Year 2022 / Volume 114 / Number 2
Original
Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori

89-95

DOI: 10.17235/reed.2021.7931/2021

Carolina Moreno Márquez, Paula Fernández Álvarez, Teresa Valdés Delgado, Luisa Castro Laria, Federico Argüelles Arias, Ángel Caunedo Álvarez, Blas José Gómez Rodríguez,

Abstract
Introduction: the primary goal of this study was to compare gastrointestinal symptom reduction in patients on bismuth-containing quadruple eradication therapy supplemented with Lactobacillus reuteri strains (DSM 17938 and ATCC PTA 6475) or placebo. Materials and methods: this was a randomized, double-blind, parallel-arm, placebo-controlled clinical trial. Patients received a first-line eradication regimen based on bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride (three-in-one capsules) and omeprazole 40 mg twice a day for ten days, plus a probiotic or placebo tablet for 30 days. During follow-up, gastrointestinal symptoms were assessed using an evaluation scale (GSRS), and adverse events were collected at 0, 14, 28 and 56 days. Results: a total of 80 patients were included from February 2018 to May 2019 at a single site. Eradication therapy was effective in 85 % of patients, with no differences between treatment arms. In the group receiving the probiotic, abdominal pain decreased in 42 % of patients, compared with 19 % in the control group (OR: 0.27; CI, 0.13-0.58; p < 0.001), and abdominal distension decreased in 25 % versus 17 % in the control group (OR: 0.24; IC, 0.19-0.84; p < 0.001); Conclusions: treatment with L. reuteri only reduced abdominal pain and distension. Further studies are needed to establish the role of probiotics as adjuvant therapy in H. pylori eradication.
Share Button
New comment
Comments

10/02/2022 21:27:36
%


References
1. Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: Factors that modulate disease risk. Clinical Microbiology Reviews 2010;23:713-39.
2. Gisbert JP. Enfermedades relacionadas con la infección por Helicobacter pylori. Gastroenterol Hepatol 2015;38:39-48.
3. Gisbert JP, Molina-Infante J, Amador J, et al. IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterologia y Hepatologia 2016;39:697-721.
4. Homan M, Orel R. Are probiotics useful in Helicobacter pylori eradication? World Journal of Gastroenterology 2015;21:10644-53.
5. Zheng X, Lyu L, Mei Z. Lactobacillus-containing probiotic supplementation increases helicobacter pylori eradication rate: Evidence from a meta-analysis. Rev Esp Enfermedades Dig 2013;105:445-53.
6. Vítor JMB, Vale FF. Alternative therapies for Helicobacter pylori: Probiotics and phytomedicine. FEMS Immunology and Medical Microbiology 2011;63:153-64.
7. Martínez Gómez JM, Giraldi MP. Infección por Helicobacter pylori en niños. En: Protocolos de la Asociación Española de Pediatría, Editores. Protocolos diagnóstico-terapéuticos de Gastroenterología, Hepatología y Nutrición pediátrica SEGHNP-AEP. Ergón; 2010. p. 93-8.
8. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection - The Maastricht IV/ Florence consensus report. Gut 2012;61:646-64.
9. Mirchev KIA, Stamboliyska M. The Effect of L. reuteri (ProGastria) on the Eradication Rate in Elderly Patients Infected with H. Pylori: a Randomized, Double-Blinded, Placebo Controlled Trial. J Probiotics Heal 2015;03:1-6.
10. Dore MP, Goni E, Di Mario F. Is There a Role for Probiotics in Helicobacter pylori Therapy? Gastroenterology Clinics of North America 2015;44:565-75.
11. Svedlund J, Sjödin I, Dotevall G. GSRS-A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988;33:129-34.
12. Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: Systematic review and meta-analysis of sequential therapy. BMJ 2013;347:f4587.
13. Barrios Andrés J, Fernández Salazar L. Estudio randomizado, doble ciego, controlado con Placebo, sobre la utilidad del probiótico Lactobacillus reuteri en la terapia de erradicación cuádruple de la infección por Helicobacter pylori, en la práctica clínica habitual”. AEMPS 2021. Disponible en: https://reec.aemps.es/reec/estudio/2017-000342-22.
14. Shah A, Talley NJ, Walker M, et al. Is There a Link Between H. Pylori and the Epidemiology of Crohn's Disease? Dig Dis Sci 2017;62(9):2472-80.
15. Talley NJ, Fullerton S, Junghard O, et al. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001;96:1998-2004.
16. Mehta RS, Abu-Ali GS, Drew DA, et al. Stability of the human faecal microbiome in a cohort of adult men. Nat Microbiol 2018;3:347-55.
Related articles

Letter

Encephalopathy in short bowel syndrome: a diagnostic challenge

DOI: 10.17235/reed.2022.8826/2022

Special Article

V Spanish Consensus Conference on Helicobacter pylori infection treatment

DOI: 10.17235/reed.2021.8358/2021

Letter to the Editor

A question about dyspeptic patients analyzed using psychometric scores

DOI: 10.17235/reed.2017.5401/2017

Letter to the Editor

Acute psychotic episode secondary to Helicobacter pylori eradication treatment

DOI: 10.17235/reed.2017.4482/2016

Citation tools
Moreno Márquez C, Fernández Álvarez P, Valdés Delgado T, Castro Laria L, Argüelles Arias F, Caunedo Álvarez Á, et all. Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori. 7931/2021


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 10932 visits.
This article has been downloaded 767 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 01/03/2021

Accepted: 13/04/2021

Online First: 05/05/2021

Published: 07/02/2022

Article revision time: 38 days

Article Online First time: 65 days

Article editing time: 343 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology